NCT05323890 2023-03-14
Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.
Shandong Cancer Hospital and Institute
Phase 2 Unknown
Shandong Cancer Hospital and Institute
RenJi Hospital